In contrast, MIR31HG was found to be downregulated in gastric cancer hepatocellular carcinoma and esophageal squamous cell carcinoma, and this downregulation was associated with aggressive clinicopathological features and poor prognoses [38–41]. This evidence concerns the gene MIR31HG and gastric cancer.